Cargando…
Pharmacogenetic Expression of CYP2C19 in a Pediatric Population
Genetic variability in CYP2C19 may be associated with both lack of efficacy and toxicity of drugs due to its different metabolic status based on the presence of particular alleles. This literature review summarizes current knowledge relative to the association or treatment adaptation based on CYP2C1...
Autores principales: | Pierre-François, Marie Josette Déborah, Gagné, Vincent, Brukner, Ivan, Krajinovic, Maja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504170/ https://www.ncbi.nlm.nih.gov/pubmed/36143168 http://dx.doi.org/10.3390/jpm12091383 |
Ejemplares similares
-
The pharmacogenetics of imatinib
por: Dulucq, Stéphanie, et al.
Publicado: (2010) -
Characterization of the microDNA through the response to chemotherapeutics in lymphoblastoid cell lines
por: Mehanna, Pamela, et al.
Publicado: (2017) -
Pharmacogenetics of asparaginase in acute lymphoblastic leukemia
por: Abaji, Rachid, et al.
Publicado: (2019) -
An in vitro selection scheme for oligonucleotide probes to discriminate between closely related DNA sequences
por: Brukner, Ivan, et al.
Publicado: (2007) -
Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin‐Induced Cutaneous Adverse Drug Reactions
por: Fohner, Alison E., et al.
Publicado: (2020)